An observational study in Melanoma Neoplasms, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-07.
Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational
the study aims to implement new approaches for the identification of circulating tumor cells and circulating microRNAs, which aim to silence the expression of genes and thus prevent the production of proteins in patients with advanced melanoma (uval, mucosal, of unknown origin). It also aims to verify whether their expression can be related to the prognosis of the disease and the response to treatments.
Here we propose a study to identify a technique for the isolation of circulating tumor cells (CTCs) from blood samples of patients with diagnosis of metastatic melanoma (uveal, mucosal, from primary unknown) to identify a potential role of CTCs and to study the role for circulating microRNAs (miRNAs) in the management of metastatic UM, MM and MUP.
3,006 studies on the registry are indexed under Melanoma; 520 are open to participants now.
This study's planned enrollment of 35 is below the median of 182 across 438 observational studies indexed under Melanoma.
Browse Melanoma studies →IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 493 studies on the registry; 273 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with diagnosis of metastatic UM or MM or MUP will be enrolled
Exclusion Criteria:
Melanoma circulating tumor cell (CTC) count (number of CTC/ml)
Evaluate CTCs count (number/ml) in patients with metastatic UM, MM and MUP
Time frame: At enrollment and at every scheduled follow-up visits throughtout the study (24 months)
Circulating microRNAs (copies/ml)
Evaluate circulating microRNAs expression (copies/ul) in patients with metastatic UM, MM and MUP
Time frame: At enrollment and at every scheduled follow-up visits throughtout the study (24 months)
Overall Survival (OS)
Evaluate OS throughtout the study period in order to correlate levels of CTC and microRNA with OS of patients with metastatic UM, MM and MUP
Time frame: Throughtout the study duration (24 months) for a minumum of 6 months for each patient
To correlate the count of CTC and the expression of circulating microRNAs with patients' prognosis in order to discover liquid biomarkers for prognosis of UM, MM and MUP
Evaluate PFS throughtout the study period in order to correlate levels of CTC and microRNA with PFS of patients with metastatic UM, MM and MUP
Time frame: Throughtout the study duration (24 months) for a minumum of 6 months for each patient
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Azienda Ospedaliero-Universitaria di Bologna